Introduction: Cisplatin-induced acute kidney injury (AKI) is primarily caused by oxidative stress from reactive oxygen species (ROS) accumulation. Developing ROS scavengers presents promising ...

Armed with $68 million in Series B funding, Epicrispr Biotechnologies (Epic) is initiating human trials of its lead candidate EPI-321, an epigenetic therapy for the neuromuscular disorder ...

“The latest findings for our next-generation farnesyl transferase inhibitor, KO-2806, being presented at this year’s AACR Annual Meeting, add to the growing body of data demonstrating the ...